Budget impact analysis of a new prostate cancer risk index for prostate cancer detection (Q46098777)

19 December 2017

title

Budget impact analysis of a new prostate cancer risk index for prostate cancer detection (English)

1 reference

19 December 2017

1 reference

1 reference

19 December 2017

Steven J Jacobsen

1 reference

19 December 2017

author name string

J Wu

1 reference

19 December 2017

J J An

1 reference

19 December 2017

J Huang

1 reference

19 December 2017

D Denham

1 reference

19 December 2017

S Frencher

1 reference

19 December 2017

publication date

3 May 2011

1 reference

19 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

19 December 2017

volume

1 reference

19 December 2017

issue

1 reference

19 December 2017

page(s)

253-261

1 reference

19 December 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Screening for prostate cancer remains controversial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate specific antigen best practice statement: 2009 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

American Cancer Society guideline for the early detection of prostate cancer: update 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen in the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen test use reported in the 2000 National Health Interview Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Racial differences in operating characteristics of prostate cancer screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Screening for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.16

31 March 2020

Identifiers

DOI

10.1038/PCAN.2011.16

1 reference

19 December 2017

1 reference

19 December 2017